EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multicenter phase II study of irinotecan as second line chemotherapy in metastatic colorectal cancer after prior exposure to infusional 5-FU based chemotherapy



Multicenter phase II study of irinotecan as second line chemotherapy in metastatic colorectal cancer after prior exposure to infusional 5-FU based chemotherapy



European Journal of Cancer 37(Supplement 6): S293, October




(PDF same-day service: $19.90)

Accession: 035349869

Download citation: RISBibTeXText

DOI: 10.1016/S0959-8049(01)81572-0



Related references

Multicenter phase II study of cetuximab and irinotecan as third line chemotherapy in patients (pts) with metastatic colorectal cancer (MCRC) previously treated with both irinotecan and oxaliplatin regimens. Journal of Clinical Oncology 24(18_suppl): 13551-13551, 2016

Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer. Bmc Cancer 15(): 626-626, 2016

Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy. Journal of ChemoTherapy 20(5): 622-631, 2008

Irinotecan (CPT-11) as first-line monotherapy in patients with advanced, metastatic colorectal cancer refractory to 5-fluorouracil adjuvant chemotherapy: a multicenter phase II study. Clinical and Translational Oncology 4(7): 385-390, 2002

S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102). International Journal of Clinical Oncology 21(4): 705-712, 2016

Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil. Anti-Cancer Drugs 15(5): 473-477, 2004

Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer - Results from a prospective cohort study. Clinical Epidemiology 7(): 295-303, 2015

Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study. Cancer ChemoTherapy and Pharmacology 64(4): 657-663, 2009

Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. Journal of Clinical Oncology 17(3): 907-913, 1999

Safety and antitumor activity of arsenic trioxide plus infusional 5-fluorouracil, leucovorin, and irinotecan as second-line chemotherapy for refractory metastatic colorectal cancer: A pilot study from South India. Indian Journal of Cancer 54(4): 631-633, 2018

A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study. Journal of Cancer Research and Clinical Oncology 141(1): 153-160, 2015

Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet. Oncology 11(9): 853-860, 2010

Extended phase I study of capecitabine and weekly irinotecan as first-line chemotherapy in metastatic colorectal cancer. European Journal of Cancer 37(Supplement 6): S290-S291, October, 2001

A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer. Drug Design, Development and Therapy 9(): 1653-1662, 2016

Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study. Annals of Oncology 14(9): 1442-1448, 2003